Patent 12371685

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (3)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2023-06-28 · reel 005995/0426 · Assignment

    HALOZYME THERAPEUTICS, INC.HALOZYME, INC.

    Correspondent: Matthew J. Van Eman

    Internal reorg

  2. 2023-06-28 · reel 005995/0423 · Assignment

    CONNOR, ROBERT JAMES, WEI, GE, ZHAO, QipingHALOZYME THERAPEUTICS, INC.

    Correspondent: Matthew J. Van Eman

    Internal reorg

  3. 2023-06-28 · reel 005995/0420 · Assignment

    SHEPARD, H. MICHAELHALOZYME, INC.

    Correspondent: Matthew J. Van Eman

    Internal reorg

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Ge Wei (Halozyme Inc)
  • H. Michael Shepard (Halozyme Inc)
  • Qiping Zhao (Halozyme Inc)
  • Robert James Connor (Halozyme Inc)

No unusual patterns observed regarding inventor departures.

Original assignee

The original assignee is Halozyme Inc. Halozyme Inc. is a biotechnology company focused on developing and commercializing oncology therapies and other products that use its ENHANZE® drug delivery technology, which is based on recombinant human hyaluronidase PH20. Halozyme Inc. is currently an operating company.

Assignment timeline

  • 2023-06-28 (executed) / recorded 2023-06-28 — Reel 005995/0426

    • Conveyance: Assignment
    • Assignor: HALOZYME THERAPEUTICS, INC.
    • Assignee: HALOZYME, INC.
    • Correspondent: Matthew J. Van Eman, Halozyme, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121.
    • Context: Internal reorg

  • 2023-06-28 (executed) / recorded 2023-06-28 — Reel 005995/0423

    • Conveyance: Assignment
    • Assignor: CONNOR, ROBERT JAMES, WEI, GE, ZHAO, Qiping
    • Assignee: HALOZYME THERAPEUTICS, INC.
    • Correspondent: Matthew J. Van Eman, Halozyme, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121. This correspondent recurs in this chain.
    • Context: Internal reorg

  • 2023-06-28 (executed) / recorded 2023-06-28 — Reel 005995/0420

    • Conveyance: Assignment
    • Assignor: SHEPARD, H. MICHAEL
    • Assignee: HALOZYME, INC.
    • Correspondent: Matthew J. Van Eman, Halozyme, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121. This correspondent recurs in this chain.
    • Context: Internal reorg

Timeline diagram

timeline
    title Ownership of US 12371685
    2023 : Assigned to Halozyme Therapeutics Inc
         : Assigned to Halozyme Inc
         : Assigned to Halozyme Inc
    2025 : Issued

NPE / troll-pattern signals

  1. Shell-entity transfer — not present. All recorded assignments are to Halozyme Therapeutics, Inc. or Halozyme, Inc., both of which appear to be operating companies involved in drug development.
  2. Known asserter in the chain — not present. Neither Halozyme Therapeutics, Inc. nor Halozyme, Inc. appear on common NPE lists.
  3. Repeat correspondent across the chain — present. Matthew J. Van Eman of Halozyme, Inc. is listed as the correspondent for all three recorded assignments on 2023-06-28 (Reel 005995/0426, 005995/0423, 005995/0420).
  4. Cascading transfers — not present. While there are multiple assignments on the same day, they appear to be internal reorganizational transfers within the Halozyme corporate structure, not consecutive transfers through chained LLCs.
  5. Pre-litigation transfer — not present. The assignments occurred in 2023, and the patent was published in 2025. No litigation has been identified prior to or immediately following these assignments.
  6. Bankruptcy fire-sale — not present. No indication of Halozyme Inc. or Halozyme Therapeutics, Inc. being in bankruptcy.
  7. Privateering — unclear. There is no publicly available information in the provided patent text or Google Patents legal events to suggest privateering.
  8. Defensive aggregator (anti-NPE) — not present. The chain does not terminate at a known defensive aggregator.

Verdict

Insufficient data. Although Halozyme is an operating company, the assignment records are limited to internal transfers before patent issuance. Without evidence of product embodiment or assertion activity post-issuance, it is not possible to conclusively determine if this patent is currently being used for operating-company assertion. A PTAB case (PGR2025-00087) is pending, which may provide more insight into potential assertion activities.

USPTO Assignment Center search page: https://assignmentcenter.uspto.gov/

Generated 5/26/2026, 12:48:38 PM